BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors
BRAF mutations have been identified as targetable, oncogenic mutations in many cancers. Given the paucity of treatments for primary brain tumors and the poor prognosis associated with high-grade gliomas, BRAF mutations in glioma are of considerable interest. In this review, we present the spectrum o...
Spremljeno u:
| Glavni autori: | , , |
|---|---|
| Format: | Revisão |
| Jezik: | engleski |
| Izdano: |
2019
|
| Online pristup: | https://doi.org/10.3390/cancers11091262 https://www.mdpi.com/2072-6694/11/9/1262/pdf |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|